Andrew Pecora

Title: Andrew Pecora and Cardiac Injury Repair

Introduction

Andrew Pecora is a U.S.-based inventor associated with Amorcyte, Inc. His work includes an invention focused on improving perfusion in infarcted heart tissue and repairing vascular injury after a heart attack.

Latest Patents

The supplied information identifies one patent titled “Infarct Area Perfusion-Improving Compositions and Methods of Vascular Injury Repair.” It describes a treatment for a revascularized patient following an acute myocardial infarction. The method administers a sterile pharmaceutical composition parenterally through a catheter. Its primary therapeutic agent is a nonexpanded, sterile, isolated chemotactic hematopoietic stem cell product, with an optional compatible second therapeutic agent.

The described cell product contains enriched autologous CD34+ cells, including a subpopulation that expresses CXCR-4 and has CXCR-4-mediated chemotactic activity. The specified composition provides at least 0.5 × 10⁶ potent CD34+ cells with these characteristics. The supplied data lists 0 patents for Pecora, so the patent’s association with him should be understood as information provided in the request rather than a verified patent count.

Career Highlights

Pecora’s listed career connection is Amorcyte, Inc., a company associated with the development of cell-based approaches to treating cardiovascular injury. The described invention reflects an effort to use targeted stem-cell therapy to support recovery in damaged heart tissue.

Collaborations

The available information connects Pecora with Amorcyte, Inc. It does not specify additional collaborators or institutional partnerships.

Conclusion

Andrew Pecora is associated with an invention proposing catheter-delivered, CXCR-4-active CD34+ cell therapy to improve perfusion and support repair after myocardial infarction.